Identifying molecular signatures in young patients with rhabdomyosarcoma
Identification de Signatures moléculaires spécifiques Dans le Rhabdomyosarcome de l'Enfant, de l'Adolescent et du Jeune Adulte, Par Analyse Spatiale du protéome Par spectrométrie de Masse
This study is trying to find specific proteins in tumor samples from young patients with rhabdomyosarcoma to help understand their cancer better and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 0 Years to 25 Years |
| Sex | All |
| Sponsor | Lille University Academic / other |
| Locations | 1 site (Lille, Nord) |
| Trial ID | NCT06924463 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on developing spatial proteomics to analyze small tumor samples from patients diagnosed with rhabdomyosarcoma. By utilizing mass spectrometry, the research aims to identify molecular signatures associated with different tumor regions, subtypes, and treatment resistance. The study will analyze pre-existing formalin-fixed paraffin-embedded (FFPE) samples and clinical data to uncover potential protein biomarkers that could inform targeted therapies. No patient interventions are involved, as the study relies on previously collected biological samples.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 0 to 25 years who have been histologically diagnosed with rhabdomyosarcoma and have received care at the Oscar Lambret Center.
Not a fit: Patients who do not have available biological samples from their diagnosis or are under guardianship may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new biomarkers that improve treatment strategies for rhabdomyosarcoma in young patients.
How similar studies have performed: While this approach is innovative, similar studies using spatial proteomics have shown promise in other cancer types, suggesting potential for success in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 0 and 25 years at the time of initial diagnosis * Diagnosis of rhabdomyosarcoma confirmed histologically * Care at the Oscar Lambret Center between January 2005 and November 2024 * No objection to the re-use of data and biological samples collected as part of care for research activities. Exclusion Criteria: * Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret; * Patient under guardianship or trusteeship.
Where this trial is running
Lille, Nord
- Oscar Lambret Center — Lille, Nord, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.